Novo Nordisk initiates patent suit to stop Ozempic copies
The firm wants to stop competitors from launching generic versions of Ozempic on the US market.
by marketwire, translated by catherine brett
Danish pharmaceutical firm Novo Nordisk has filed a patent suit in order to prevent competitors from launching copies of Ozempic on the US market, Bloomberg News reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk sues Teva over generic drug development
For subscribers
.jpg)
Genmab CEO expects more legal twists in future
For subscribers
